Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126

Microvascular Research

Volumn 71, Issue 2, 2006, Pages 76-84

  Cullis, Elizabeth R ^a   Kalber, Tammy L ^a   Ashton, Susan E ^b   Cartwright, Judith E ^a   Griffiths, John R ^a   Ryan, Anderson J ^b   Robinson, Simon P ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Angiogenesis; Nitric oxide; Tumour perfusion; ZD6126

Indexed keywords

HOE 33342; INDUCIBLE NITRIC OXIDE SYNTHASE; N ACETYLCOLCHINOL PHOSPHATE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN; HUMAN CELL; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; PERFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN; STATISTICAL SIGNIFICANCE; TUMOR; TUMOR GROWTH; VASCULARIZATION; WESTERN BLOTTING; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MICE; MICE, INBRED STRAINS; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE SYNTHASE TYPE II; ORGANOPHOSPHORUS COMPOUNDS; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS;

ANIMALIA; MURINAE;

EID: 33646063560     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2006.01.004     Document Type: Article

References (53)

1. Ambs S., Merriam W.G., Bennett W.P., et al. Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res. 58 (1998) 334-341
2. Ambs S., Merriam W.G., Ogunfusika M.O., et al. p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat. Med. 4 (1998) 1371-1376
3. Anderson H.L., Yap J.T., Miller M.P., et al. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J. Clin. Oncol. 21 (2003) 2823-2830
4. Blakey D.C., Westwood F.R., Walker M., et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin. Cancer Res. 8 (2002) 1974-1983
5. Boucher Y., Baxter L.T., and Jain R.K. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res. 50 (1990) 4478-4484
6. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 9 (2003) 653-660
7. Chaplin D.J., Durand R.E., and Olive P.L. Cell selection from a murine tumour using the fluorescent probe Hoechst 33342. Br. J. Cancer 51 (1985) 569-572
8. Chinje E.C., and Stratford I.J. Role of nitric oxide in growth of solid tumours: a balancing act. Essays Biochem. 32 (1997) 61-72
9. Cobbs C.S., Brenman J.E., Aldape K.D., et al. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res. 55 (1995) 727-730
10. Davis P.D., Dougherty G.J., Blakey D.C., et al. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res. 62 (2002) 7247-7253
11. Davis P.D., Tozer G.M., Naylor M.A., et al. Enhancement of vascular targeting by inhibitors of nitric oxide synthase. Int. J. Radiat. Oncol. Biol. Phys. 54 (2002) 1532-1536
12. Evelhoch J.L., LoRusso P.M., He Z., et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin. Cancer Res. 10 (2004) 3650-3657
13. Fukumura D., Yuan F., Endo M., et al. Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions. Am. J. Pathol. 150 (1997) 713-725
14. Gallo O., Masini E., Morbidelli L., et al. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J. Natl. Cancer Inst. 90 (1998) 587-596
15. Goertz D.E., Yu J.L., Kerbel R.S., et al. High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow. Cancer Res. 62 (2002) 6371-6375
16. Goto H., Yano S., Zhang H., et al. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice. Cancer Res. 62 (2002) 3711-3715
17. Groom A.C. The Microcirculatory Society Eugene M. Landis award lecture. microcirculation of the spleen: new concepts, new challenges. Microvasc. Res. 34 (1987) 269-289
18. Guffroy M., Dally C., Vrignaud P., et al. Evaluation of tissue perfusion (tumor, spleen, heart) in mice after administration of AVE8062, a tumor vascular-targeting agent. Proceedings of the American Association for Cancer Research, Orlando (2004) 5438
19. Heldin C.H., Rubin K., Pietras K., et al. High interstitial fluid pressure-An obstacle in cancer therapy. Nat. Rev., Cancer 4 (2004) 806-813
20. Hellmuth M., Paulukat J., Ninic R., et al. Nitric oxide differentially regulates pro- and anti-angiogenic markers in DLD-1 colon carcinoma cells. FEBS Lett. 563 (2004) 98-102
21. Horsman M.R., and Murata R. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int. J. Radiat. Oncol. Biol. Phys. 57 (2003) 1047-1055
22. Jadeski L.C., and Lala P.K. Nitric oxide synthase inhibition by N(G)-nitro-l-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am. J. Pathol. 155 (1999) 1381-1390
23. Jenkins D.C., Charles I.G., Thomsen L.L., et al. Roles of nitric oxide in tumor growth. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 4392-4396
24. Kostourou V., Robinson S.P., Cartwright J.E., et al. Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis. Br. J. Cancer 87 (2002) 673-680
25. Kostourou V., Robinson S.P., Whitley G.S., et al. Effects of overexpression of dimethylarginine dimethylaminohydrolase on tumor angiogenesis assessed by susceptibility magnetic resonance imaging. Cancer Res. 63 (2003) 4960-4966
26. Kostourou V., Troy H., Murray J.F., et al. Overexpression of dimethylarginine dimethylaminohydrolase enhances tumor hypoxia: an insight into the relationship of hypoxia and angiogenesis in vivo. Neoplasia 6 (2004) 401-411
27. Kubes P., and Granger D.N. Nitric oxide modulates microvascular permeability. Am. J. Physiol. 262 (1992) H611-H615
28. Loibl S., Buck A., Strank C., et al. The role of early expression of inducible nitric oxide synthase in human breast cancer. Eur. J. Cancer 41 (2005) 265-271
29. Micheletti G., Poli M., Borsotti P., et al. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res. 63 (2003) 1534-1537
30. Moncada S., Palmer R.M., and Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharm. Rev. 43 (1991) 109-142
31. Papapetropoulos A., Garcia-Cardena G., Madri J.A., et al. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J. Clin. Invest. 100 (1997) 3131-3139
32. Parkins C.S., Dennis M.F., Stratford M.R., et al. Ischemia reperfusion injury in tumors: the role of oxygen radicals and nitric oxide. Cancer Res. 55 (1995) 6026-6029
33. Parkins C.S., Holder A.L., Hill S.A., et al. Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide. Br. J. Cancer 83 (2000) 811-816
34. Ragan D.M., Schmidt E.E., MacDonald I.C., et al. Spontaneous cyclic contractions of the capillary wall in vivo, impeding red cell flow: a quantitative analysis. Evidence for endothelial contractility. Microvasc. Res. 36 (1988) 13-30
35. Reveneau S., Arnould L., Jolimoy G., et al. Nitric oxide synthase in human breast cancer is associated with tumor grade, proliferation rate, and expression of progesterone receptors. Lab. Invest. 79 (1999) 1215-1225
36. Rijken P.F., Bernsen H.J., and van der Kogel A.J. Application of an image analysis system to the quantitation of tumor perfusion and vascularity in human glioma xenografts. Microvasc. Res. 50 (1995) 141-153
37. Robinson S.P., McIntyre D.J.O., Checkley D., et al. Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br. J. Cancer 88 (2003) 1592-1597
38. Robinson S.P., Kalber T.L., Howe F.A., et al. Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging. Clin. Cancer Res. (2005) 466-474
39. Siemann D.W., and Rojiani A.M. Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int. J. Radiat. Oncol. Biol. Phys. 54 (2002) 1512-1517
40. Siemann D.W., and Rojiani A.M. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int. J. Radiat. Oncol. Biol. Phys. 53 (2002) 164-171
41. Siemann D.W., Chaplin D.J., and Horsman M.R. Vascular-targeting therapies for treatment of malignant disease. Cancer 100 (2004) 2491-2499
42. Thomsen L.L., Lawton F.G., Knowles R.G., et al. Nitric oxide synthase activity in human gynecological cancer. Cancer Res. 54 (1994) 1352-1354
43. Thomsen L.L., Miles D.W., Happerfield L., et al. Nitric oxide synthase activity in human breast cancer. Br. J. Cancer 72 (1995) 41-44
44. Thomsen L.L., Scott J.M., Topley P., et al. Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: studies with 1400 W, a novel inhibitor. Cancer Res. 57 (1997) 3300-3304
45. Tozer G.M., Prise V.E., Wilson J., et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. 59 (1999) 1626-1634
46. Tozer G.M., Kanthou C., and Baguley B.C. Disrupting tumour blood vessels. Nat. Rev., Cancer 5 (2005) 423-435
47. Trachtman H., Futterweit S., Garg P., et al. Nitric oxide stimulates the activity of a 72-kDa neutral matrix metalloproteinase in cultured rat mesangial cells. Biochem. Biophys. Res. Commun. 218 (1996) 704-708
48. Wachsberger P.R., Burd R., and Dicker A.P. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin. Cancer Res. 9 (2003) 1957-1971
49. Wachsberger P.R., Burd R., Marero N., et al. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin. Cancer Res. 11 (2005) 835-842
50. Wink D.A., Vodovotz Y., Laval J., et al. The multifaceted roles of nitric oxide in cancer. Carcinogenesis 19 (1998) 711-721
51. Yamaguchi S., Bell H.S., Shinoda J., et al. Glioma tumourgenicity is decreased by iNOS knockout: experimental studies using the C6 striatal implantation glioma model. Br. J. Neurosurg. 16 (2002) 567-572
52. Yancopoulos G.D., Davis S., Gale N.W., et al. Vascular-specific growth factors and blood vessel formation. Nature 407 (2000) 242-248
53. Ziche M., Morbidelli L., Choudhuri R., et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J. Clin. Invest. 99 (1997) 2625-2634